Search

Displaying results 731 - 740 of 4588 in total
  1. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.

  2. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48676] Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects. … Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals.

  3. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development … It was discovered by scientists at the National Institutes of Health (NIH) and was first developed by _Isis Pharmaceuticals_ and subsequently licensed to _Novartis_ [A31990].

  4. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 20...

  5. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160] … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

  6. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.

  7. Drug

    Famotidine

    go.drugbank.com/drugs/DB00927
    ApprovedInvestigational

    [L11166] Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory

  8. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [A246609] Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications. … [A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4.

  9. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant...

  10. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.